Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics IncfiledCriticalCyclerion Therapeutics Inc
Priority claimed from PCT/US2017/049834external-prioritypatent/WO2018045276A1/en
Publication of MA46096B1publicationCriticalpatent/MA46096B1/fr
Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose